Table 3.
Univariate Cox regression analyses for overall survival and relapse-free survival in 104 ovarian carcinomas and 63 high-grade serous carcinomas.
| Characteristics | No. | OS | RFS | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| OVERALL OVARIAN CARCINOMAS (n = 104) | |||||
| Age, y, ≥ 60 (vs. < 60) | 33/104 | 2.647 (1.554–4.511) | < 0.001 | 2.248 (1.375–3.673) | 0.001 |
| Stage, III & IV (vs. I & II) | 52/104 | 3.232 (1.809–5.774) | < 0.001 | 3.898 (2.269–6.695) | < 0.001 |
| Tumor size, cm, > 10 (vs. ≤ 10) | 36/104 | 0.502 (0.270–0.936) | 0.030 | 0.588 (0.342–1.012) | 0.055 |
| LN metastasis, presence (vs. absence) | 20/104 | 1.382 (0.739–2.583) | 0.311 | 1.738 (0.996–3.035) | 0.052 |
| Ascites, presence (vs. absence) | 33/104 | 1.902 (1.106–3.272) | 0.020 | 1.825 (1.111–2.998) | 0.018 |
| Bilaterality, bilateral (vs. unilateral) | 45/104 | 1.612 (0.947–2.745) | 0.079 | 2.050 (1.254–3.350) | 0.004 |
| CA125, elevated (vs. normal) | 75/93 | 5.013 (1.554–16.167) | 0.007 | 4.873 (1.760–13.490) | 0.002 |
| Histologic grade, high (vs. low) | 77/104 | 3.626 (1.548–8.493) | 0.003 | 3.605 (1.715–7.582) | < 0.001 |
| Nu-SIRT6, positive (vs. negative) | 36/104 | 3.280 (1.908–5.638) | < 0.001 | 3.252 (1.977–5.349) | < 0.001 |
| Cy-SIRT6, positive (vs. negative) | 49/104 | 1.583 (0.930–2.696) | 0.091 | 1.952 (1.194–3.190) | 0.008 |
| Nu-Aβ-catenin, positive (vs. negative) | 56/104 | 2.940 (1.638–5.278) | < 0.001 | 3.761 (2.172–6.512) | < 0.001 |
| Cy-Aβ-catenin, positive (vs. negative) | 59/104 | 2.417 (1.348–4.334) | 0.003 | 2.889 (1.673–4.987) | < 0.001 |
| HIGH-GRADE SEROUS CARCINOMAS (n = 63) | |||||
| Age, y, ≥ 60 (vs. < 60) | 27/63 | 2.043 (1.125–3.710) | 0.019 | 1.648 (0.954–2.848) | 0.073 |
| Stage, III & IV (vs. I & II) | 38/63 | 1.953 (1.009–3.782) | 0.047 | 2.838 (1.502–5.364) | 0.001 |
| Tumor size, cm, > 10 (vs. ≤ 10) | 15/63 | 0.773 (0.371–1.612) | 0.492 | 0.811 (0.424–1.551) | 0.526 |
| LN metastasis, presence (vs. absence) | 15/63 | 1.401 (0.714–2.749) | 0.327 | 1.804 (0.975–3.337) | 0.060 |
| Ascites, presence (vs. absence) | 26/63 | 1.349 (0.740–2.459) | 0.329 | 1.357 (0.782–2.355) | 0.277 |
| Bilaterality, bilateral (vs. unilateral) | 36/63 | 1.339 (0.719–2.493) | 0.358 | 1.593 (0.893–2.841) | 0.115 |
| CA125, elevated (vs. normal) | 53/58 | 2.454 (0.590–10.218) | 0.217 | 1.614 (0.500–5.211) | 0.424 |
| Nu-SIRT6, positive (vs. negative) | 26/63 | 2.433 (1.323–4.475) | 0.004 | 2.211 (1.261–3.878) | 0.006 |
| Cy-SIRT6, positive (vs. negative) | 34/63 | 1.126 (0.621–2.041) | 0.696 | 1.216 (0.702–2.105) | 0.485 |
| Nu-Aβ-catenin, positive (vs. negative) | 45/63 | 3.284 (1.515–7.118) | 0.003 | 3.600 (1.781–7.275) | < 0.001 |
| Cy-Aβ-catenin, positive (vs. negative) | 46/63 | 1.682 (0.830–3.411) | 0.149 | 1.672 (0.874–3.198) | 0.120 |
Nu-SIRT6, nuclear expression of SIRT6; Cy-SIRT6, cytoplasmic expression of SIRT6; Nu-Aβ-catenin, nuclear expression of active β-catenin; Cy-Aβ-catenin, cytoplasmic expression of active β-catenin; LN, lymph node.